| October 2028Month disclosed | pozelimab (REGN3918) | REGN | Primary completion | Paroxysmal Nocturnal Hemoglobinuria | Scheduled | ClinicalTrials.gov |
| October 2028Month disclosed | aln-ang3 | REGN | Primary completion | Diabetic Kidney Disease (DKD) | Scheduled | ClinicalTrials.gov |
| Nov 2028 to Feb 2029Quarter disclosed | olatorepatide (HS-20094) | REGN | Topline readout | Hidradenitis Suppurativa | Scheduled | ClinicalTrials.gov |
| November 2028Month disclosed | olatorepatide (HS-20094) | REGN | Primary completion | Hidradenitis Suppurativa | Scheduled | ClinicalTrials.gov |
| Dec 2028 to Mar 2029Quarter disclosed | olatorepatide (HS-20094) | REGN | Topline readout | Overweight or Obesity Without Diabetes | Scheduled | ClinicalTrials.gov |
| December 2028Month disclosed | olatorepatide (HS-20094) | REGN | Primary completion | Overweight or Obesity Without Diabetes | Scheduled | ClinicalTrials.gov |
| Jan to Apr 2029Quarter disclosed | aln-cideb | REGN | Topline readout | Metabolic Dysfunction-Associated Steatohepatitis; MASH | Scheduled | ClinicalTrials.gov |
| January 2029Month disclosed | aln-cideb | REGN | Primary completion | Metabolic Dysfunction-Associated Steatohepatitis; MASH | Scheduled | ClinicalTrials.gov |
| Mar to Jun 2029Quarter disclosed | cenvacibart (REGN7508) | REGN | Topline readout | Atrial Fibrillation (AF) | Scheduled | ClinicalTrials.gov |
| Mar to Jun 2029Quarter disclosed | aln-cideb | REGN | Topline readout | Metabolic Dysfunction-Associated Steatotic Liver Disease; MASLD | Scheduled | ClinicalTrials.gov |
| March 2029Month disclosed | aln-cideb | REGN | Primary completion | Metabolic Dysfunction-Associated Steatotic Liver Disease; MASLD | Scheduled | ClinicalTrials.gov |
| March 2029Month disclosed | cenvacibart (REGN7508) | REGN | Primary completion | Atrial Fibrillation (AF) | Scheduled | ClinicalTrials.gov |
| May to Aug 2029Quarter disclosed | Lynozyfic (linvoseltamab) | REGN | Topline readout | Relapsed and/or Refractory Multiple Myeloma (RRMM) | Scheduled | ClinicalTrials.gov |
| May to Aug 2029Quarter disclosed | regn-2cat | REGN | Topline readout | Allergic Conjunctivitis | Scheduled | ClinicalTrials.gov |
| May to Aug 2029Quarter disclosed | aln-cideb | REGN | Topline readout | Alcohol-Associated Liver Disease; ALD | Scheduled | ClinicalTrials.gov |
| May 2029Month disclosed | aln-cideb | REGN | Primary completion | Alcohol-Associated Liver Disease; ALD | Scheduled | ClinicalTrials.gov |
| May 2029Month disclosed | Lynozyfic (linvoseltamab) | REGN | Primary completion | Relapsed and/or Refractory Multiple Myeloma (RRMM) | Scheduled | ClinicalTrials.gov |
| May 2029Month disclosed | regn-2cat | REGN | Primary completion | Allergic Conjunctivitis | Scheduled | ClinicalTrials.gov |
| Jun to Sep 2029Quarter disclosed | cenvacibart (REGN7508) | REGN | Topline readout | Venous Thromboembolism (VTE) | Scheduled | ClinicalTrials.gov |
| June 2029Month disclosed | cenvacibart (REGN7508) | REGN | Primary completion | Venous Thromboembolism (VTE) | Scheduled | ClinicalTrials.gov |
| Jul to Oct 2029Quarter disclosed | Ordspono™ (odronextamab) | REGN | Topline readout | Follicular Lymphoma (FL) | Scheduled | ClinicalTrials.gov |
| July 2029Month disclosed | Ordspono™ (odronextamab) | REGN | Primary completion | Follicular Lymphoma (FL) | Scheduled | ClinicalTrials.gov |
| Aug to Nov 2029Quarter disclosed | cenvacibart (REGN7508) | REGN | Topline readout | Peripheral Artery Disease (PAD) | Scheduled | ClinicalTrials.gov |
| August 2029Month disclosed | cenvacibart (REGN7508) | REGN | Primary completion | Peripheral Artery Disease (PAD) | Scheduled | ClinicalTrials.gov |
| Sep to Dec 2029Quarter disclosed | cenvacibart (REGN7508) | REGN | Topline readout | Atrial Fibrillation (AF) | Scheduled | ClinicalTrials.gov |
| September 2029Month disclosed | cenvacibart (REGN7508) | REGN | Primary completion | Atrial Fibrillation (AF) | Scheduled | ClinicalTrials.gov |
| Dec 2029 to Mar 2030Quarter disclosed | REGN10597 | REGN | Topline readout | Non Small Cell Lung Cancer; NSCLC | Scheduled | ClinicalTrials.gov |
| Dec 2029 to Mar 2030Quarter disclosed | cenvacibart (REGN7508) | REGN | Topline readout | Secondary Stroke | Scheduled | ClinicalTrials.gov |
| December 2029Month disclosed | REGN10597 | REGN | Primary completion | Non Small Cell Lung Cancer; NSCLC | Scheduled | ClinicalTrials.gov |
| December 2029Month disclosed | cenvacibart (REGN7508) | REGN | Primary completion | Secondary Stroke | Scheduled | ClinicalTrials.gov |
| Jan to Apr 2030Quarter disclosed | fianlimab (REGN3767) | REGN | Topline readout | Non-small Cell Lung Cancer | Scheduled | ClinicalTrials.gov |
| Jan to Apr 2030Quarter disclosed | pozelimab (REGN3918) | REGN | Topline readout | Paroxysmal Nocturnal Hemoglobinuria | Scheduled | ClinicalTrials.gov |
| Jan to Apr 2030Quarter disclosed | cenvacibart (REGN7508) | REGN | Topline readout | Cancer-Associated Thrombosis (CAT) | Scheduled | ClinicalTrials.gov |
| January 2030Month disclosed | fianlimab (REGN3767) | REGN | Primary completion | Non-small Cell Lung Cancer | Scheduled | ClinicalTrials.gov |
| January 2030Month disclosed | pozelimab (REGN3918) | REGN | Primary completion | Paroxysmal Nocturnal Hemoglobinuria | Scheduled | ClinicalTrials.gov |
| January 2030Month disclosed | cenvacibart (REGN7508) | REGN | Primary completion | Cancer-Associated Thrombosis (CAT) | Scheduled | ClinicalTrials.gov |
| Mar to Jun 2030Quarter disclosed | aln-pnp | REGN | Topline readout | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Scheduled | ClinicalTrials.gov |
| March 2030Month disclosed | aln-pnp | REGN | Primary completion | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Scheduled | ClinicalTrials.gov |
| May to Aug 2030Quarter disclosed | Libtayo® (cemiplimab) | REGN | Topline readout | Cutaneous Squamous Cell Carcinoma (CSCC) | Scheduled | ClinicalTrials.gov |
| May 2030Month disclosed | Libtayo® (cemiplimab) | REGN | Primary completion | Cutaneous Squamous Cell Carcinoma (CSCC) | Scheduled | ClinicalTrials.gov |
| Jun to Sep 2030Quarter disclosed | ubamatamab (REGN4018) | REGN | Topline readout | — | Scheduled | ClinicalTrials.gov |
| June 2030Month disclosed | ubamatamab (REGN4018) | REGN | Primary completion | — | Scheduled | ClinicalTrials.gov |
| Jul to Oct 2030Quarter disclosed | Pasatru (garetosmab) | REGN | Topline readout | Fibrodysplasia Ossificans Progressiva; FOP | Scheduled | ClinicalTrials.gov |
| July 2030Month disclosed | Pasatru (garetosmab) | REGN | Primary completion | Fibrodysplasia Ossificans Progressiva; FOP | Scheduled | ClinicalTrials.gov |
| Oct 2030 to Jan 2031Quarter disclosed | fianlimab+cemiplimab (REGN3767) | REGN | Topline readout | Melanoma | Scheduled | ClinicalTrials.gov |
| October 2030Month disclosed | fianlimab+cemiplimab (REGN3767) | REGN | Primary completion | Melanoma | Scheduled | ClinicalTrials.gov |
| Nov 2030 to Feb 2031Quarter disclosed | Libtayo® (cemiplimab) | REGN | Topline readout | Locally Advanced Basal Cell Carcinoma | Scheduled | ClinicalTrials.gov |
| November 2030Month disclosed | Libtayo® (cemiplimab) | REGN | Primary completion | Locally Advanced Basal Cell Carcinoma | Scheduled | ClinicalTrials.gov |